{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:24Z","timestamp":1786987044795,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900118"],"award-info":[{"award-number":["81900118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2023xkj138"],"award-info":[{"award-number":["2023xkj138"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clinthera.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:38:22Z","timestamp":1749843502000},"page":"595-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Grapefruit Juice Combined With Low-Dose Venetoclax in AML Patients Ineligible for Intensive Chemotherapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Danchen","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuXin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhengFeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0692-1935","authenticated-orcid":false,"given":"Zhangbiao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.05.008_bib0001","first-page":"S2352","article-title":"Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia","author":"Candoni","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0003","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","article-title":"Acute myeloid leukemia: historical perspective and progress in research and therapy over 5 decades","volume":"21","author":"Kantarjian","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0006","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0007","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11912-020-00987-8","article-title":"Access to therapy for acute myeloid leukemia in the developing world: barriers and solutions","volume":"22","author":"Meillon-Garcia","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0008","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/cpt.2968","article-title":"Physiologically based pharmacokinetic modeling of bergamottin and 6,7-dihydroxybergamottin to describe CYP3A4 mediated grapefruit-drug interactions","volume":"114","author":"Fuhr","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0009","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bcp.15590","article-title":"Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: A proof-of-concept case study","volume":"89","author":"De la Garza-Salazar","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jpba.2019.01.022","article-title":"Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry","volume":"166","author":"Wang","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40262-021-01054-6","article-title":"Population pharmacokinetics and safety of Dasatinib in Chinese children with core-binding factor acute myeloid leukemia","volume":"61","author":"Yang","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0012","first-page":"960","article-title":"Efficacy and safety of venetoclax-based induction therapy in acute myeloid leukemia","volume":"31","author":"Feng","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jcph.2140","article-title":"Impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics: A PBPK and population PK-informed analysis","volume":"63","author":"Mukherjee","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0014","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40273-022-01145-7","article-title":"Cost-effectiveness analysis of venetoclax in combination with Azacitidine versus Azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: from a US third party payer perspective","volume":"40","author":"Pratz","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0016","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0017","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/16078454.2020.1843752","article-title":"The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0018","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","article-title":"Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies","volume":"50","author":"Hachem","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2025.05.008_bib0019","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/bjh.19116","article-title":"Invasive fungal infection following venetoclax and posaconazole co-administration","volume":"203","author":"Reynolds","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:02:45Z","timestamp":1762246965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0149291825001729"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Grapefruit Juice Combined With Low-Dose Venetoclax in AML Patients Ineligible for Intensive Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}